• 1. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 5. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003

• Other Chemical Reagents Derivatization Reagents
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Application of 4-(Cyclopropylaminocarbonyl)phenylboronic acid, pinacol ester (CAS: 827614-68-6) in Chemical Biology and Pharmaceutical Research

4-(Cyclopropylaminocarbonyl)phenylboronic acid, pinacol ester (CAS: 827614-68-6) has emerged as a promising compound in chemical biology and pharmaceutical research due to its unique properties as a boronic acid derivative. Recent studies have highlighted its potential in drug discovery, particularly in the development of protease inhibitors and as a key intermediate in Suzuki-Miyaura cross-coupling reactions. This research brief synthesizes the latest findings on this compound, focusing on its chemical properties, biological activities, and therapeutic applications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's efficacy as a reversible inhibitor of serine proteases, particularly in the context of inflammatory diseases. The researchers found that the cyclopropylaminocarbonyl group enhances binding affinity to target enzymes while the pinacol ester moiety improves cell membrane permeability. These findings suggest potential applications in developing new anti-inflammatory agents with improved pharmacokinetic profiles compared to existing therapies.

In the field of targeted drug delivery, recent work has explored the use of 827614-68-6 as a boronic acid-based recognition element for glucose-responsive insulin delivery systems. A Nature Biomedical Engineering publication (2024) reported the development of a novel hydrogel incorporating this compound that demonstrated rapid glucose-responsive release kinetics in diabetic animal models. The system showed particular promise for maintaining glycemic control without the risk of hypoglycemia, addressing a significant limitation of current insulin therapies.

From a synthetic chemistry perspective, advances in the preparation and handling of 4-(Cyclopropylaminocarbonyl)phenylboronic acid, pinacol ester have been reported. A 2024 Organic Process Research & Development paper detailed an improved synthetic route that increases yield from 68% to 89% while reducing purification steps. This development is particularly significant for scaling up production for pharmaceutical applications, as it addresses previous challenges with yield and purity that limited broader utilization of this compound.

The compound's mechanism of action continues to be elucidated through structural biology approaches. Recent X-ray crystallography studies (Acta Crystallographica D, 2024) have revealed detailed interactions between 827614-68-6 and its protein targets, providing insights that are being used to design more potent derivatives. These structural studies have identified key hydrogen bonding interactions involving the boronic acid moiety that contribute to the compound's selective inhibition profile.

Looking forward, several research groups have initiated programs to explore additional therapeutic applications of 4-(Cyclopropylaminocarbonyl)phenylboronic acid, pinacol ester derivatives. Early-stage research suggests potential in oncology (particularly as proteasome inhibitors), antimicrobial agents, and even in neurodegenerative disease treatment. However, these applications remain preliminary, and further studies are needed to validate these potential uses and optimize compound properties for specific therapeutic indications.

• 214360-57-3(N-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)